Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 17/20 | 0.52 |
| ▸ | EGFR | P00533 | 15/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4726959 | 0.81 | EGFR (0.66) | CSF1REGFRPRMT5 | |
| SCHEMBL4737885 | 0.80 | ERBB2 (0.65) | CSF1REGFR | |
| SCHEMBL4726940 | 0.79 | EGFR (0.52) | CSF1REGFRPRMT5 | |
| SCHEMBL4764721 | 0.78 | EGFR (0.71) | CSF1REGFR | |
| SCHEMBL27603008 | 0.78 | EGFR (0.71) | CSF1REGFR | |
| SCHEMBL4338377 | 0.77 | KDR (0.55) | CSF1REGFR | |
| SCHEMBL4729350 | 0.76 | KDR (0.55) | CSF1REGFR | |
| SCHEMBL4730479 | 0.76 | HDAC1 (0.63) | CSF1REGFR | |
| SCHEMBL4741288 | 0.75 | ERBB2 (0.56) | CSF1REGFR | |
| SCHEMBL4342995 | 0.75 | KDR (0.51) | CSF1REGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, TYMP, TYMS | CSF1R 3516/4885EGFR 2694/4885PRMT5 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.